ORTHO CYCLEN-21
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 59m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO CYCLEN-21 is an oral contraceptive tablet containing norgestimate and ethinyl estradiol, approved by the FDA in 1989. It is a combined oral contraceptive indicated for pregnancy prevention in women of reproductive age. The drug works by suppressing ovulation through hormonal mechanisms, with the 21-day formulation requiring a 7-day hormone-free interval.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely in transition or contraction mode, suggesting limited growth opportunities and potential workforce restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORTHO CYCLEN-21 offers limited career growth given its LOE-approaching status and zero linked job openings. Roles on this product are typically maintenance-focused, emphasizing retention and cost management rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on ORTHO CYCLEN-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.